ECSP055568A - Composición de comprimido de liberación sostenida de pramipexol - Google Patents
Composición de comprimido de liberación sostenida de pramipexolInfo
- Publication number
- ECSP055568A ECSP055568A EC2005005568A ECSP055568A ECSP055568A EC SP055568 A ECSP055568 A EC SP055568A EC 2005005568 A EC2005005568 A EC 2005005568A EC SP055568 A ECSP055568 A EC SP055568A EC SP055568 A ECSP055568 A EC SP055568A
- Authority
- EC
- Ecuador
- Prior art keywords
- sustained release
- composition
- pramipexol
- release compressed
- compressed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
La presente invención se refiere a formulaciones de comprimido, y más particularmente a una composición de comprimido de liberación sostenida para la administración oral de un fármaco o profármaco soluble en agua, ejemplificado por diclorhidrato de pramipexol.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39842702P | 2002-07-25 | 2002-07-25 | |
US39844702P | 2002-07-25 | 2002-07-25 | |
US47951303P | 2003-06-18 | 2003-06-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP055568A true ECSP055568A (es) | 2005-04-18 |
Family
ID=31192087
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2005005568A ECSP055568A (es) | 2002-07-25 | 2005-01-24 | Composición de comprimido de liberación sostenida de pramipexol |
Country Status (41)
Country | Link |
---|---|
US (2) | US20050226926A1 (es) |
EP (2) | EP1987832A1 (es) |
JP (1) | JP4700963B2 (es) |
KR (1) | KR100712832B1 (es) |
CN (1) | CN1313092C (es) |
AP (1) | AP2201A (es) |
AR (1) | AR040681A1 (es) |
AT (1) | ATE406162T1 (es) |
AU (1) | AU2003261241B2 (es) |
BR (1) | BR0312960A (es) |
CA (1) | CA2492854C (es) |
CR (1) | CR7661A (es) |
CU (1) | CU23440B7 (es) |
CY (1) | CY1110408T1 (es) |
DE (1) | DE60323235D1 (es) |
DK (1) | DK1531814T3 (es) |
EA (2) | EA009663B1 (es) |
EC (1) | ECSP055568A (es) |
ES (1) | ES2310673T3 (es) |
GE (1) | GEP20074048B (es) |
HK (1) | HK10777456A1 (es) |
HR (1) | HRP20041235B1 (es) |
IL (1) | IL166078A0 (es) |
IS (1) | IS7623A (es) |
MA (1) | MA27328A1 (es) |
ME (1) | MEP52308A (es) |
MX (1) | MXPA05001054A (es) |
MY (1) | MY138846A (es) |
NO (1) | NO334298B1 (es) |
NZ (1) | NZ537790A (es) |
OA (1) | OA13303A (es) |
PA (1) | PA8578301A1 (es) |
PE (1) | PE20040130A1 (es) |
PL (1) | PL215587B1 (es) |
PT (1) | PT1531814E (es) |
RS (1) | RS51719B (es) |
SI (1) | SI1531814T1 (es) |
TW (1) | TWI347849B (es) |
UY (1) | UY27912A1 (es) |
WO (1) | WO2004010997A1 (es) |
ZA (1) | ZA200500439B (es) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060281797A1 (en) * | 2001-12-11 | 2006-12-14 | University Of Virginia Patent Foundation | Neurorestoration with R(+) Pramipexole |
EP2305252A1 (en) * | 2001-12-11 | 2011-04-06 | University Of Virginia Patent Foundation | Use of pramipexole to treat amyotrophic lateral sclerosis |
US20050226926A1 (en) | 2002-07-25 | 2005-10-13 | Pfizer Inc | Sustained-release tablet composition of pramipexole |
US20070196481A1 (en) * | 2002-07-25 | 2007-08-23 | Amidon Gregory E | Sustained-release tablet composition |
MY142204A (en) * | 2002-07-25 | 2010-10-29 | Pharmacia Corp | Pramipexole once-daily dosage form |
US9101155B2 (en) | 2003-07-11 | 2015-08-11 | Asahi Kasei Chemicals Corporation | Functional starch powder |
MX2007001850A (es) * | 2004-08-13 | 2007-03-28 | Boehringer Ingelheim Int | Formulacion de pildora de liberacion prolongada que contiene pramipexol o una sal farmaceuticamente aceptable del mismo, metodo para fabricarlo y uso del mismo. |
EP1781260B2 (en) * | 2004-08-13 | 2014-04-02 | Boehringer Ingelheim International GmbH | Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
SI1803447T1 (sl) * | 2004-09-09 | 2010-01-29 | Psicofarma S A De C V | Farmacevtski sestavek za zadrĺ˝evano sproĺ äśanje hidralazina in njegova uporaba kot podrpora zdravljenju raka |
EP1731514A1 (en) * | 2005-06-02 | 2006-12-13 | Sandoz AG | Process for the preparation of Pramipexole |
CA2619217A1 (en) * | 2005-08-15 | 2007-02-22 | University Of Virginia Patent Foundation | Neurorestoration with r(+) pramipexole |
WO2007090883A1 (en) * | 2006-02-10 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Extended release formulation |
WO2007090882A2 (en) * | 2006-02-10 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical extended release compositions comprising pramipexole |
US20090041844A1 (en) * | 2006-02-10 | 2009-02-12 | Boehringer Ingelheim International Gmbh | Modified Release Formulation |
US8518926B2 (en) | 2006-04-10 | 2013-08-27 | Knopp Neurosciences, Inc. | Compositions and methods of using (R)-pramipexole |
US20070259930A1 (en) * | 2006-04-10 | 2007-11-08 | Knopp Neurosciences, Inc. | Compositions and methods of using r(+) pramipexole |
CA2652251A1 (en) * | 2006-05-16 | 2007-11-29 | Knopp Neurosciences, Inc. | Compositions of r(+) and s(-) pramipexole and methods for using the same |
WO2008001204A2 (en) * | 2006-06-29 | 2008-01-03 | Antares Pharma Ipl Ag | Transdermal compositions of pramipexole having enhanced permeation properties |
US8524695B2 (en) * | 2006-12-14 | 2013-09-03 | Knopp Neurosciences, Inc. | Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same |
WO2008113056A2 (en) * | 2007-03-14 | 2008-09-18 | Knopp Neurosciences, Inc. | Synthesis of chirally purified substituted benzothiazole diamines |
EP2150239A1 (en) * | 2007-04-24 | 2010-02-10 | Boehringer Ingelheim International GmbH | Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof |
WO2008150741A1 (en) * | 2007-06-04 | 2008-12-11 | Drugtech Corporation | Controlled release dopamine agonist compositions |
US20090304794A1 (en) * | 2008-06-09 | 2009-12-10 | Supernus Pharmaceuticals, Inc. | Controlled release formulations of pramipexole |
US20110190356A1 (en) | 2008-08-19 | 2011-08-04 | Knopp Neurosciences Inc. | Compositions and Methods of Using (R)- Pramipexole |
CN102802418A (zh) * | 2009-06-19 | 2012-11-28 | 诺普神经科学股份有限公司 | 用于治疗肌萎缩性侧索硬化的组合物和方法 |
CA2767029A1 (en) * | 2009-07-02 | 2011-01-06 | Supernus Pharmaceuticals, Inc. | A method of treatment of a neurological disorder |
WO2011037976A2 (en) * | 2009-09-22 | 2011-03-31 | Dr. Reddy's Laboratories Limited | Pramipexole pharmaceutical formulations |
WO2011086182A2 (en) | 2010-01-18 | 2011-07-21 | Synthon Bv | Pramipexole extended release tablets |
TR201001862A1 (tr) | 2010-03-11 | 2011-10-21 | Sanovel �La� San.Ve T�C.A.�. | Kontrollü salım gerçekleştiren pramipeksol formülasyonları. |
AU2011256928A1 (en) | 2010-05-24 | 2012-12-20 | Lupin Limited | Extended release formulation of pramipexole |
KR101307334B1 (ko) | 2010-07-02 | 2013-09-12 | 주식회사 바이오파마티스 | 프라미펙솔 또는 이의 약학적으로 허용되는 염을 포함하는 안정성이 개선된 서방형 약학 조성물 |
WO2013034173A1 (en) | 2011-09-06 | 2013-03-14 | Synthon Bv | Pramipexole extended release tablets |
WO2013096816A1 (en) | 2011-12-22 | 2013-06-27 | Biogen Idec Ma Inc. | Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds |
EP2732812A1 (de) | 2012-11-15 | 2014-05-21 | Aristo Pharma GmbH | Pramipexol-Retardtablettenformulierung |
US9662313B2 (en) | 2013-02-28 | 2017-05-30 | Knopp Biosciences Llc | Compositions and methods for treating amyotrophic lateral sclerosis in responders |
US9468630B2 (en) | 2013-07-12 | 2016-10-18 | Knopp Biosciences Llc | Compositions and methods for treating conditions related to increased eosinophils |
CN105764507B (zh) | 2013-07-12 | 2019-07-19 | 诺普生物科学有限责任公司 | 治疗升高的嗜酸性粒细胞和/或嗜碱性粒细胞的水平 |
ES2871556T3 (es) | 2013-08-13 | 2021-10-29 | Knopp Biosciences Llc | Composiciones y métodos para el tratamiento de la urticaria crónica |
ES2813674T3 (es) | 2013-08-13 | 2021-03-24 | Knopp Biosciences Llc | Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b |
CN103520128B (zh) | 2013-10-12 | 2018-08-21 | 石家庄杏林锐步医药科技股份有限公司 | 一种普拉克索的缓释片剂、制备方法及其用途 |
US11160809B2 (en) | 2017-04-10 | 2021-11-02 | Chase Therapeutics Corporation | NK1-antagonist combination and method for treating synucleinopathies |
BR112019028034A2 (pt) | 2017-06-30 | 2020-07-07 | Chase Therapeutics Corporation | composições de antagonista de nk-1 e métodos para uso no tratamento da depressão |
CN109316466B (zh) * | 2017-07-31 | 2022-04-05 | 深圳翰宇药业股份有限公司 | 一种盐酸普拉克索缓释制剂及其制备方法 |
US11234961B2 (en) | 2017-08-17 | 2022-02-01 | Zi-Qiang Gu | Pamoate salt of monoamine anti-Parkinson's agents, method of preparation and use thereof |
CN113876729B (zh) * | 2021-11-11 | 2023-05-30 | 南通联亚药业股份有限公司 | 一种盐酸普拉克索缓释片剂及其制备方法 |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US15735A (en) * | 1856-09-16 | Improvement in harvesters | ||
US2887440A (en) * | 1957-08-12 | 1959-05-19 | Dow Chemical Co | Enteric coating |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
JPS58403B2 (ja) | 1975-07-24 | 1983-01-06 | 武田薬品工業株式会社 | L− アスコルビンサンセイザイノ セイゾウホウ |
US4140755A (en) | 1976-02-13 | 1979-02-20 | Hoffmann-La Roche Inc. | Sustained release tablet formulations |
CH649215A5 (de) | 1981-04-29 | 1985-05-15 | Hoffmann La Roche | Pharmazeutische praeparate. |
SE8103843L (sv) | 1981-06-18 | 1982-12-19 | Astra Laekemedel Ab | Farmaceutisk mixtur |
US4424235A (en) | 1981-09-14 | 1984-01-03 | Hoffmann-La Roche Inc. | Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor |
ATE45735T1 (de) | 1984-12-22 | 1989-09-15 | Thomae Gmbh Dr K | Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arnzneimittel. |
DE3447075A1 (de) * | 1984-12-22 | 1986-07-03 | Dr. Karl Thomae Gmbh, 7950 Biberach | Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arzneimittel |
US4738851A (en) | 1985-09-27 | 1988-04-19 | University Of Iowa Research Foundation, Inc. | Controlled release ophthalmic gel formulation |
US4709712A (en) | 1986-10-22 | 1987-12-01 | Dermatalogical Products Of Texas | Polycarboxylic acid polymer gels as protective agents |
GB8828020D0 (en) | 1988-12-01 | 1989-01-05 | Unilever Plc | Topical composition |
US5026559A (en) | 1989-04-03 | 1991-06-25 | Kinaform Technology, Inc. | Sustained-release pharmaceutical preparation |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
DE69016430T2 (de) | 1989-06-09 | 1995-06-01 | Upjohn Co | Heterozyklische amine mit zns-wirksamkeit. |
US5273975A (en) | 1989-06-09 | 1993-12-28 | The Upjohn Company | Heterocyclic amines having central nervous system activity |
GB9015822D0 (en) | 1990-07-18 | 1990-09-05 | Beecham Group Plc | Compositions |
US5472712A (en) * | 1991-12-24 | 1995-12-05 | Euroceltique, S.A. | Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
US5656296A (en) * | 1992-04-29 | 1997-08-12 | Warner-Lambert Company | Dual control sustained release drug delivery systems and methods for preparing same |
US5431920A (en) | 1993-09-21 | 1995-07-11 | Merck Frosst, Canada, Inc. | Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents |
US5458887A (en) * | 1994-03-02 | 1995-10-17 | Andrx Pharmaceuticals, Inc. | Controlled release tablet formulation |
WO1997004752A1 (en) * | 1995-07-26 | 1997-02-13 | Duramed Pharmaceuticals, Inc. | Pharmaceutical compositions of conjugated estrogens and methods for their use |
ES2248908T7 (es) | 1997-06-06 | 2014-11-24 | Depomed, Inc. | Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles |
AU739261B2 (en) * | 1997-07-01 | 2001-10-11 | Pfizer Inc. | Sertraline salts and sustained-release dosage forms of sertraline |
US5895663A (en) | 1997-07-31 | 1999-04-20 | L. Perrigo Company | Pseudoephedrine hydrochloride extended-release tablets |
CA2211778A1 (en) * | 1997-08-14 | 1999-02-14 | Francois Carriere | Preparation of pregelatinized high amylose starch and debranched starch useful as an excipient for controlled release of active agents |
US7153845B2 (en) | 1998-08-25 | 2006-12-26 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
US6624200B2 (en) | 1998-08-25 | 2003-09-23 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
US6248358B1 (en) | 1998-08-25 | 2001-06-19 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets and methods of making and using the same |
DE69819748T2 (de) | 1997-09-12 | 2004-09-30 | Columbia Laboratories (Bermuda) Ltd. | Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen |
US6197339B1 (en) * | 1997-09-30 | 2001-03-06 | Pharmacia & Upjohn Company | Sustained release tablet formulation to treat Parkinson's disease |
US6056977A (en) * | 1997-10-15 | 2000-05-02 | Edward Mendell Co., Inc. | Once-a-day controlled release sulfonylurea formulation |
GB9802201D0 (en) * | 1998-02-03 | 1998-04-01 | Cerestar Holding Bv | Free-flowable directly compressible starch as binder,disintegrant and filler for compresion tablets and hard gelatine capsules |
WO1999045924A1 (en) | 1998-03-11 | 1999-09-16 | Smithkline Beecham Plc | Composition |
GB9812426D0 (en) | 1998-06-10 | 1998-08-05 | Reckitt & Colmann Prod Ltd | Improvements in or relating to organic compositions |
TW407058B (en) * | 1998-07-17 | 2000-10-01 | Dev Center Biotechnology | Oral cisapride dosage forms with an extended duration |
DE19906290A1 (de) | 1999-02-15 | 2000-08-17 | Falk Pharma Gmbh | Arzneimittel zur Behandlung bzw. Prävention von Darmkrebs |
US7374779B2 (en) | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
EP1169024B1 (en) | 1999-03-31 | 2005-12-21 | Janssen Pharmaceutica N.V. | Pregelatinized starch in a controlled release formulation |
DE19927688A1 (de) | 1999-06-17 | 2000-12-21 | Gruenenthal Gmbh | Mehrschichttablette zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac |
ES2246485T3 (es) | 1999-07-01 | 2006-02-16 | PHARMACIA & UPJOHN COMPANY LLC | (s,s)-reboxetina para tratar la incontinencia. |
AU5060499A (en) | 1999-08-04 | 2001-03-05 | Ranbaxy Laboratories Limited | Hydrodynamically balanced oral drug delivery system |
US6387403B1 (en) | 1999-09-15 | 2002-05-14 | Alza Corporation | Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing |
CA2384840A1 (en) | 1999-09-30 | 2001-04-05 | The General Hospital Corporation | Use of pramipexole as a treatment for cocaine craving |
US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
MXPA02006150A (es) * | 1999-12-22 | 2004-09-06 | Pharmacia Corp | Formulaciones de liberacion sostenida de un inhibidor de ciclooxigenasa-2. |
CA2332691C (en) | 2000-01-27 | 2007-11-27 | The York Group, Inc. | Death care merchandising system |
PT1257277E (pt) | 2000-02-24 | 2005-09-30 | Pharmacia & Upjohn Co Llc | Novas combinacoes de farmacos |
US6277875B1 (en) * | 2000-07-17 | 2001-08-21 | Andrew J. Holman | Use of dopamine D2/D3 receptor agonists to treat fibromyalgia |
ES2187249B1 (es) | 2000-09-18 | 2004-09-16 | Synthon Bv | Procedimiento para la preparacion de 2-amino-6-(alquil)amino-4,5,6,7-tetrahidrobenzotiazoles. |
SE0004671D0 (sv) | 2000-12-15 | 2000-12-15 | Amarin Dev Ab | Pharmaceutical formulation |
DE10138275A1 (de) | 2001-08-10 | 2003-02-27 | Boehringer Ingelheim Pharma | Verbindungen zur Beseitigung der Anhedonie |
CA2470636A1 (en) | 2001-12-20 | 2003-07-03 | Pharmacia Corporation | Zero-order sustained released dosage forms and method of making the same |
CA2488860A1 (en) | 2002-07-25 | 2004-02-05 | Pharmacia Corporation | Method of preparing solid dosage forms coated in two layers comprising a water-insoluble polymer and a water-soluble pore former |
US20050226926A1 (en) | 2002-07-25 | 2005-10-13 | Pfizer Inc | Sustained-release tablet composition of pramipexole |
US20070196481A1 (en) | 2002-07-25 | 2007-08-23 | Amidon Gregory E | Sustained-release tablet composition |
MY142204A (en) | 2002-07-25 | 2010-10-29 | Pharmacia Corp | Pramipexole once-daily dosage form |
US20040121010A1 (en) | 2002-10-25 | 2004-06-24 | Collegium Pharmaceutical, Inc. | Pulsatile release compositions of milnacipran |
AU2003224467A1 (en) | 2003-03-11 | 2004-09-30 | Korea United Pharm, Inc. | Process for the preparing of hardcapsule formulation containing lansoprazole |
JP2006522099A (ja) | 2003-04-04 | 2006-09-28 | ファルマシア コーポレーション | 複合粒状体からなる経口徐放性圧縮錠 |
US20050020589A1 (en) | 2003-06-18 | 2005-01-27 | Pfizer Inc. | Sustained-release tablet composition comprising a dopamine receptor agonist |
EP1781260B2 (en) | 2004-08-13 | 2014-04-02 | Boehringer Ingelheim International GmbH | Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
MX2007001850A (es) | 2004-08-13 | 2007-03-28 | Boehringer Ingelheim Int | Formulacion de pildora de liberacion prolongada que contiene pramipexol o una sal farmaceuticamente aceptable del mismo, metodo para fabricarlo y uso del mismo. |
WO2006046256A1 (en) | 2004-10-27 | 2006-05-04 | Alembic Limited | Extended release formulation of pramipexole dihydrochloride |
WO2007002518A1 (en) | 2005-06-23 | 2007-01-04 | Spherics, Inc. | Delayed release or extended-delayed release dosage forms of pramipexole |
WO2007002516A2 (en) | 2005-06-23 | 2007-01-04 | Spherics, Inc. | Improved dosage forms for movement disorder treatment |
CA2619217A1 (en) | 2005-08-15 | 2007-02-22 | University Of Virginia Patent Foundation | Neurorestoration with r(+) pramipexole |
WO2007054976A2 (en) | 2005-11-08 | 2007-05-18 | Panacea Biotec Ltd. | Lipid based controlled release pharmaceutical composition |
WO2007090882A2 (en) | 2006-02-10 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical extended release compositions comprising pramipexole |
WO2007090883A1 (en) | 2006-02-10 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Extended release formulation |
US20090041844A1 (en) | 2006-02-10 | 2009-02-12 | Boehringer Ingelheim International Gmbh | Modified Release Formulation |
EP1886665A1 (en) | 2006-08-01 | 2008-02-13 | Boehringer Ingelheim Pharma GmbH & Co. KG | Gastro retentive delivery system |
-
2003
- 2003-07-23 US US10/626,166 patent/US20050226926A1/en not_active Abandoned
- 2003-07-24 PA PA20038578301A patent/PA8578301A1/es unknown
- 2003-07-24 PE PE2003000734A patent/PE20040130A1/es not_active Application Discontinuation
- 2003-07-24 MY MYPI20032784A patent/MY138846A/en unknown
- 2003-07-24 AR AR20030102666A patent/AR040681A1/es unknown
- 2003-07-25 AP AP2005003205A patent/AP2201A/xx active
- 2003-07-25 BR BR0312960-8A patent/BR0312960A/pt not_active IP Right Cessation
- 2003-07-25 OA OA1200500016A patent/OA13303A/en unknown
- 2003-07-25 PL PL375696A patent/PL215587B1/pl unknown
- 2003-07-25 DK DK03771807T patent/DK1531814T3/da active
- 2003-07-25 RS YU20050059A patent/RS51719B/sr unknown
- 2003-07-25 TW TW092120406A patent/TWI347849B/zh not_active IP Right Cessation
- 2003-07-25 ES ES03771807T patent/ES2310673T3/es not_active Expired - Lifetime
- 2003-07-25 MX MXPA05001054A patent/MXPA05001054A/es active IP Right Grant
- 2003-07-25 EP EP08159203A patent/EP1987832A1/en not_active Withdrawn
- 2003-07-25 WO PCT/US2003/023205 patent/WO2004010997A1/en active IP Right Grant
- 2003-07-25 SI SI200331350T patent/SI1531814T1/sl unknown
- 2003-07-25 CN CNB038178737A patent/CN1313092C/zh not_active Expired - Fee Related
- 2003-07-25 NZ NZ537790A patent/NZ537790A/en unknown
- 2003-07-25 DE DE60323235T patent/DE60323235D1/de not_active Expired - Lifetime
- 2003-07-25 EP EP03771807A patent/EP1531814B1/en not_active Expired - Lifetime
- 2003-07-25 JP JP2004524787A patent/JP4700963B2/ja not_active Expired - Fee Related
- 2003-07-25 EA EA200500079A patent/EA009663B1/ru not_active IP Right Cessation
- 2003-07-25 GE GEAP8599A patent/GEP20074048B/en unknown
- 2003-07-25 AT AT03771807T patent/ATE406162T1/de active
- 2003-07-25 KR KR1020057001392A patent/KR100712832B1/ko not_active IP Right Cessation
- 2003-07-25 CA CA002492854A patent/CA2492854C/en not_active Expired - Fee Related
- 2003-07-25 EA EA200702187A patent/EA200702187A1/ru unknown
- 2003-07-25 ME MEP-523/08A patent/MEP52308A/xx unknown
- 2003-07-25 PT PT03771807T patent/PT1531814E/pt unknown
- 2003-07-25 AU AU2003261241A patent/AU2003261241B2/en not_active Ceased
- 2003-07-31 UY UY27912A patent/UY27912A1/es not_active Application Discontinuation
-
2004
- 2004-12-29 IS IS7623A patent/IS7623A/is unknown
- 2004-12-30 IL IL16607804A patent/IL166078A0/xx unknown
- 2004-12-30 HR HRP20041235AA patent/HRP20041235B1/hr not_active IP Right Cessation
-
2005
- 2005-01-06 NO NO20050093A patent/NO334298B1/no not_active IP Right Cessation
- 2005-01-17 ZA ZA200500439A patent/ZA200500439B/xx unknown
- 2005-01-24 CR CR7661A patent/CR7661A/es unknown
- 2005-01-24 EC EC2005005568A patent/ECSP055568A/es unknown
- 2005-01-25 MA MA28066A patent/MA27328A1/fr unknown
- 2005-01-25 CU CU20050018A patent/CU23440B7/es not_active IP Right Cessation
- 2005-11-08 HK HK05109947A patent/HK10777456A1/xx unknown
-
2008
- 2008-10-13 CY CY20081101125T patent/CY1110408T1/el unknown
-
2010
- 2010-03-03 US US12/716,755 patent/US8399016B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP055568A (es) | Composición de comprimido de liberación sostenida de pramipexol | |
CY1120138T1 (el) | Στερεη φαρμακευτικη μορφη δοσολογιας που περιλαμβανει μια στερεη διασπορα αναστολεα πρωτεασης toy hiv | |
ECSP055569A (es) | Forma de dosificación de pramipexol en una dosis única diaria | |
BR0306870A (pt) | Composição farmacêutica oral, e, método para preparar a mesma | |
AR038527A1 (es) | Forma de dosificacion que contiene un inhibidor de la pde 4 como ingrediente activo | |
AR065809A1 (es) | Formulaciones farmaceuticas que contienen un inhibidor sglt2 | |
RS77904A (en) | Oral administration form for difficulty soluble basic active ingredients which are applied orally | |
ECSP077243A (es) | Formulación de pelet de liberación extendida que contiene pramipexol o una de sus sales farmacéuticamente aceptable, un método para su fabricación y su uso | |
CY1111470T1 (el) | Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α | |
ITMI20011337A0 (it) | Composizioni farmaceutiche orali a rilascio modificato del principio attivo | |
NO20080827L (no) | Faste doseringsformuleringer av narkotiske legemidler som har forbedret bukal adsorpsjon | |
NO20082988L (no) | Vedvarende frigivningsformulering innbefattende oktreotid og to eller flere polylaktid-ko-glykolidpolymerer | |
CY1110906T1 (el) | Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης | |
TNSN06220A1 (en) | Benzimidazole derivatives | |
TNSN07337A1 (en) | Pharmaceutical composition comprising an indolylmaleimide derivative | |
BRPI0415053A (pt) | inibidor de p-glicoproteìna, método para preparar o mesmo e composição farmacêutica que compreende o mesmo | |
BRPI0412458A (pt) | composições farmacêuticas oralmente dosadas compreendendo um agente de liberação na forma micronizada | |
ITMI20011338A0 (it) | Composizioni farmaceutiche orali a rilascio immediato del principio attivo | |
NO20083183L (no) | Fast farmasoytisk sammensetning inneholdende irbesartan | |
CR8172A (es) | Saquinavir mesilato en forma de dosificacion farmaceutica oral | |
TR200301553A1 (tr) | İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar | |
MY141008A (en) | Oral formulations of deoxypeganine and their uses | |
ATE357220T1 (de) | Pharmazeutische zusammensetzung mit modifizierter freisetzung | |
TW200716114A (en) | Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof | |
ITRM20030074A0 (it) | Formulazioni semisolide a rilascio immediato intese per la somministrazione orale di farmaci. |